According to the International Myeloma Working Group (IMWG), diagnosis of MM requires ≥10% clonal plasma cells in bone marrow or biopsy-proven plasmacytoma with CRAB features (hypercalcemia, renal dysfunction, anemia, bone lesions) or specific biomarkers such as high serum free light chain ratios (>100) [9,10]. This evidence concerns the gene TNFSF14 and anemia (phenotype).